原发性中枢神经系统淋巴瘤
小学(天文学)
淋巴瘤
癌症研究
中枢神经系统
肿瘤细胞
化学
生物
神经科学
免疫学
物理
天文
作者
Zhaoyun Liu,Rong Fu,Hui Liu,Kai Ding,Jia Song,Rong Fu
标识
DOI:10.1016/j.biopha.2024.117133
摘要
Primary central nervous system lymphoma (PCNSL) is a group of malignant brain tumors with a poor prognosis, and new therapeutic approaches for this tumor urgently need to be investigated. Formulated from a long-standing anti-inflammatory drugs, ACT001 has demonstrated in clinical research to be able to pass through the blood-brain barrier (BBB) and affect the central nervous system. The effects of ACT001 on PCNSL cell apoptosis, proliferation and immune-related indexes were detected by flow cytometry, and the efficacy of ACT001 was verified in vivo by constructing a mouse PCNSL tumor model. ACT001 significantly inhibited PCNSL cell proliferation and induced apoptosis in vitro. In addition, ACT001 can significantly inhibit the PD-1/PD-L1 expression and restore the function of T cells, so that the immune system cannot allow tumor cells to escape. In vivo experiments show that co-infusion of ACT001 and T cells effectively inhibits PCNSL tumor growth in NSG mice. Our work describes the inhibitory effect of ACT001 on the PCNSL cell line and demonstrated the inhibitory effect of ACT001 on immune checkpoints.
科研通智能强力驱动
Strongly Powered by AbleSci AI